Navigation Links
Study evaluates risk factors for chronic TMJD
Date:11/10/2011

be so difficult is the chronic pain associated with TMJD results from a highly complex biological interplay. The interplay involves myriad factors, ranging from the intricacies of pain transmission and its possible rewiring and overamplification en route to the brain to the complicating and frequent presence of other painful conditions, such as fibromyalgia and chronic fatigue, which mask or modify the symptoms of the TMJD.

With so many variables, some researchers have suggested that the best scientific entry point to examine TMJD is during its earliest stages, before the full-blown complexity of advanced disease clouds the investigative picture.

This thinking and progress in studying the basic biology of pain led to the launch of OPPERA in September 2005. It marks the first-ever, large prospective (meaning, looking forward in time) clinical study of TMJD and, more broadly, a chronic pain condition.

The OPPERA Study involves four investigative units: University of Florida in Gainesville, directed by Dr. Roger Fillingim; University of Buffalo-SUNY, directed by Dr. Richard Ohrbach; University of Maryland at Baltimore, overseen by Drs. Joel Greenspan and Ronald Dubner; and the University of North Carolina Chapel Hill, directed by Drs. Gary Slade, Eric Blair, Shad Smith, Luda Diatchenko, and William Maixner, who is also OPPERA's program director. Mr. Charles Knott, with the Battelle Memorial Institute in Columbus, Ohio, served as the director of the Data Coordination Center.

Investigators at the four study sites now have completed tracking 3,200 healthy male and female volunteers, ages 18-44, from three to five years. As expected, a subset of approximately 200 volunteers developed their first bout(s) of TMJD, and researchers are currently analyzing the study data to determine the factors associated with the disease's onset.

The publications in the Journal of Pain, however, stem from an associated but distinct baseline study a
'/>"/>

Contact: Bob Kuska
kuskar@nidcr.nih.gov
301-594-7560
NIH/National Institute of Dental and Craniofacial Research
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Groundbreaking study quantifies health costs of climate-change related disasters in the US
2. Wood biofuel could be a competitive industry by 2020: UBC study
3. Einstein study indicates brain plays role in regulating blood sugar in humans
4. Researchers using new technology to study breath for toxins
5. New study uncovers how brain cells degrade dangerous protein aggregates
6. HIV study identifies key cellular defence mechanism
7. UI researcher to study glaucoma in dogs
8. New study suggests EU biofuels are as carbon intensive as petrol
9. BGSU researchers harness power of genome institute for Great Lakes study
10. Albert Einstein College of Medicine receives $8 million from NIH to study how cancer spreads
11. Vegetarian diet, physical activity protect against diabetes in black population, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... of Yale researchers will lead a five-year, $3 million ... events is affecting the transport of dissolved organic matter ... say could alter the chemical composition and water quality ... funding from the National Science Foundation,s MacroSystems Biology program, ... the watershed, which begins in Canada and runs through ...
(Date:4/22/2014)... fist-like club of a mantis shrimp, a team of ... with University of Southern California and Purdue University, have ... more impact resistant and tougher than the standard used ... of this tiny crustacean, the more we realize its ... day," said David Kisailus, a Kavli Fellow of the ...
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... of children with undiagnosed learning disorders, developmental deficits, and ... challenges, which are explored in detail in a reflective ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... ahead of print at www.liebertpub.com/gtmb ...
... been extinct for 65 million years, newly published data ... is providing invaluable insights into their paleobiology. Ammonites, shelled ... inhabited the oceans for nearly 350 million years. Specimens ... that covered North America during the Cretaceous Period demonstrate ...
... are investigating a potential new treatment for lung disease that ... is studying how statins, drugs which are commonly used to ... , There is currently no effective treatment for acute ... rates for those who become critically ill and suffer lung ...
Cached Biology News:Unexplained childhood disorders 2New discoveries in North America's Great Plains bring ammonites to life 2New discoveries in North America's Great Plains bring ammonites to life 3Queen's University Belfast lung injury study could save lives in critically ill 2
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Therapies to Address the Underlying Cause of Cystic,Fibrosis; ... SOUTH PLAINFIELD, N.J., Aug. 20 New ... that the investigational oral drug,PTC124 demonstrates activity in ... with PTC124 results in statistically significant,improvements in the ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) announced today that ... on August 14, 2008 indicating that Oncothyreon does ... The NASDAQ Global Market,because it does not meet ... (i) the market value of Oncothyreon,s common stock ...
... Crystal Research Associates, LLC,announced today that ... on Generex Biotechnology Corporation (Nasdaq: GNBT ... at http://www.crystalra.com ., Generex Biotechnology ... pharmaceutical company that aims to research, develop, ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3